Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research

Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation

NCT00003153 ·Status: COMPLETED ·Phase: PHASE2

Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial

NCT06212323 ·Status: RECRUITING

Study of Dara-Pembro for Multiple Myeloma Patients

NCT04361851 ·Status: WITHDRAWN ·Phase: PHASE2

Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)

NCT01109407 ·Status: TERMINATED

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

NCT02728102 ·Status: COMPLETED ·Phase: PHASE2

Immunophenotyping of Plasma Cells and Immune Effector Cells in Peripheral Whole Blood and Bone Marrow Samples From Multiple Myeloma (MM) Patients

NCT05428163 ·Status: COMPLETED

Non-invasive MRD Assessment in Multiple Myeloma

NCT05625971 ·Status: COMPLETED

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

NCT03236428 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma

NCT00900263 ·Status: COMPLETED

Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma

NCT02331368 ·Status: COMPLETED ·Phase: PHASE2

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

NCT06577025 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro

NCT01472627 ·Status: COMPLETED

A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide

NCT04497961 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma

NCT05139225 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma

NCT04467281 ·Status: WITHDRAWN ·Phase: PHASE2

Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma

NCT03952832 ·Status: WITHDRAWN ·Phase: PHASE2

Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma

NCT03848676 ·Status: COMPLETED

A Dietary Study for People With Multiple Myeloma

NCT07226609 ·Status: RECRUITING ·Phase: NA

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

NCT01985126 ·Status: COMPLETED ·Phase: PHASE2

Stem Cell Translpantation in Multiple Myeloma

NCT05082675 ·Status: COMPLETED ·Phase: PHASE2

Discontinuation Study

NCT05866757 ·Status: RECRUITING ·Phase: NA

Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma

NCT04230031 ·Status: WITHDRAWN ·Phase: PHASE2

Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients

NCT04108624 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

Multiple Myeloma Minimal Residual Disease

NCT02627261 ·Status: COMPLETED

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

NCT02716805 ·Status: TERMINATED ·Phase: PHASE1